These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22541166)

  • 21. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems.
    Birzniece V; Bäckström T; Johansson IM; Lindblad C; Lundgren P; Löfgren M; Olsson T; Ragagnin G; Taube M; Turkmen S; Wahlström G; Wang MD; Wihlbäck AC; Zhu D
    Brain Res Rev; 2006 Aug; 51(2):212-39. PubMed ID: 16368148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder.
    Lan MJ; McLoughlin GA; Griffin JL; Tsang TM; Huang JT; Yuan P; Manji H; Holmes E; Bahn S
    Mol Psychiatry; 2009 Mar; 14(3):269-79. PubMed ID: 18256615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior.
    Schmidt HD; Duman RS
    Behav Pharmacol; 2007 Sep; 18(5-6):391-418. PubMed ID: 17762509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synaptic plasticity and mood disorders.
    Duman RS
    Mol Psychiatry; 2002; 7 Suppl 1():S29-34. PubMed ID: 11986993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
    Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
    Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease.
    Francis PT
    Neurodegener Dis; 2008; 5(3-4):241-3. PubMed ID: 18322401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NF-κB mediated regulation of adult hippocampal neurogenesis: relevance to mood disorders and antidepressant activity.
    Bortolotto V; Cuccurazzu B; Canonico PL; Grilli M
    Biomed Res Int; 2014; 2014():612798. PubMed ID: 24678511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult hippocampal neurogenesis in depression.
    Sahay A; Hen R
    Nat Neurosci; 2007 Sep; 10(9):1110-5. PubMed ID: 17726477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiaxial evaluation of the pathophysiology of mood disorder and therapeutic mechanisms of clinical drugs by neuronal plasticity and neuronal load].
    Omata N; Mizuno T; Mitsuya H; Wada Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):231-6. PubMed ID: 25069263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A model of hippocampal neurogenesis in memory and mood disorders.
    Becker S; Wojtowicz JM
    Trends Cogn Sci; 2007 Feb; 11(2):70-6. PubMed ID: 17174137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.
    Hashimoto K
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):341-57. PubMed ID: 20653908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of adult hippocampal neurogenesis: relevance to depression.
    Vaidya VA; Fernandes K; Jha S
    Expert Rev Neurother; 2007 Jul; 7(7):853-64. PubMed ID: 17610392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnenolone for cognition and mood in dual diagnosis patients.
    Osuji IJ; Vera-Bolaños E; Carmody TJ; Brown ES
    Psychiatry Res; 2010 Jul; 178(2):309-12. PubMed ID: 20493557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia.
    Lewis DA; Cruz D; Eggan S; Erickson S
    Ann N Y Acad Sci; 2004 Jun; 1021():64-76. PubMed ID: 15251876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current pharmacological approaches and perspectives in the treatment of geriatric mood disorders.
    Diniz BS; Nunes PV; Machado-Vieira R; Forlenza OV
    Curr Opin Psychiatry; 2011 Nov; 24(6):473-7. PubMed ID: 21918446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems.
    Joca SR; Ferreira FR; Guimarães FS
    Stress; 2007 Aug; 10(3):227-49. PubMed ID: 17613938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressants in healthy subjects: what are the psychotropic/psychological effects?
    Serretti A; Calati R; Goracci A; Di Simplicio M; Castrogiovanni P; De Ronchi D
    Eur Neuropsychopharmacol; 2010 Jul; 20(7):433-53. PubMed ID: 20079613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review.
    Tang SW; Helmeste D; Leonard B
    World J Biol Psychiatry; 2012 Sep; 13(6):402-12. PubMed ID: 22175526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volumetric reduction of cerebellum associated with cognitive, affective and behavioral changes.
    da Silva RO; Cheniaux E; Mezzasalma MA
    J Neuropsychiatry Clin Neurosci; 2012; 24(2):E21. PubMed ID: 22772683
    [No Abstract]   [Full Text] [Related]  

  • 40. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.